Quarterly ResultAug 6, 2026, 08:09 AM
Novavax Q2 Revenue $57M, Net Loss $53M; Raises FY26 Revenue Outlook
AI Summary
Novavax reported second quarter 2026 total revenue of $57 million, a 76% decrease year-over-year, and a net loss of $53 million, compared to net income of $107 million in the prior year, which benefited from significant milestones. Despite the quarterly loss, the company raised its full-year 2026 revenue framework to between $235 million and $275 million and improved its combined R&D and SG&A expense guidance. Strategic progress with Sanofi includes potential milestones of $125 million for Phase 3 trial initiation and $75 million for manufacturing technology transfer.
Key Highlights
- Q2 2026 total revenue was $57 million, a 76% decrease year-over-year.
- Reported a net loss of $53 million for Q2 2026, compared to net income of $107 million in Q2 2025.
- Basic net loss per share was $(0.32) for Q2 2026.
- Raised full-year 2026 revenue framework to between $235 million and $275 million.
- Improved full-year 2026 combined R&D and SG&A expense guidance to $370 million - $410 million.
- Sanofi Phase 3 COVID-19-Influenza Combination trial initiation to trigger a $125 million milestone.
- Sanofi manufacturing technology transfer completion expected mid-2027, triggering a $75 million milestone.
- Cash, cash equivalents, marketable securities, and restricted cash totaled $724 million as of June 30, 2026.
Price Impact
More from NVAX